Novartis Access

MSH's Douglas Keene, PharmD, MHS, Vice President, Pharmaceuticals & Health Technologies Group, was among the speakers at a recent event in Basel, Switzerland, hosted by Novartis, with representatives from NGOs, academia, and government discussing how to expand access to health in developing countries, including through the newly-launched program, Novartis Access.

MSH is partnering on Novartis Access to help empower governments of low- and lower-middle-income countries to provide access to health for chronic diseases patients who need it most. Ensuring affordable and equitable access to medicines is critical to achieving health for all -- and central to MSH's mission and health-systems strengthening approach.

 {Photo credit: Novartis}Official signing of the memorandum of understanding at the launch event, held at Kenyatta National Hospital.Photo credit: Novartis

Novartis launched Novartis Access, a novel social business program, in collaboration with the Kenyan government, Management Sciences for Health (MSH), and other partners, on Thursday, October 15, at the Kenyatta National Hospital (KNH).

Novartis Access is an industry first: “a novel social business model that aims to deliver affordable medicines for non-communicable diseases (NCDs) also known as chronic disease in lower income countries”.

MSH’s partnership with Novartis, announced in September, is to enable governments in low- and middle- countries, beginning in Kenya, Ethiopia, and Vietnam, to provide better care for their chronic diseases population in need.

Kenyan Dignitaries Describe Country-Led Efforts on Chronic Diseases

The launch event kicked off October 15, at 10 am, East Africa Time, preceded by a tour of KNH. The launch was high level, graced by the presence of Kenyan dignitaries.

Printer Friendly Version
Subscribe to RSS - Novartis Access